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Chronic administration of palmitoleic acid
reduces insulin resistance and hepatic lipid
accumulation in KK-Ay Mice with genetic type 2
diabetes
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Abstract
Background: Studies have demonstrated the beneficial effect of palmitoleic acid (C16:1 n-7) on reducing muscle
insulin resistance and preventing beta-cell apoptosis. However, the effect of palmitoleic acid on diabetes remains
to be elucidated. The aim of this study was to examine the antidiabetic effect of palmitoleic acid in KK-Ay mice, a
spontaneous model for studies of obese type 2 diabetes with low insulin sensitivity.
Methods: KK-Ay mice were orally administered vehicle, 300 mg/kg of palmitoleic acid, or 300 mg/kg of palmitic
acid (C16:0) on a daily basis for 4 weeks.
Results: Palmitoleic acid reduced body weight increase, ameliorated the development of hyperglycemia and
hypertriglyceridemia, and improved insulin sensitivity. In addition, hepatic characteristics were significantly affected,
as weight of the liver and hepatic triglyceride levels were lower in the palmitoleic acid group when compared to
the control (vehicle and palmitic acid groups). Oil red O staining clearly indicated reduced hepatic lipid
accumulation in response to palmitoleic acid. Furthermore, palmitoleic acid down-regulated mRNA expressions of
proinflammatory adipocytokine genes (TNFa and resistin) in white adipose tissue and lipogenic genes (SREBP-1, FAS,
and SCD-1) in liver.
Conclusions: These results suggest that palmitoleic acid improves hyperglycemia and hypertriglyceridemia by
increasing insulin sensitivity, in part owing to suppressing proinflammatory gene expressions and improving
hepatic lipid metabolism in diabetic mice.
Background
Type 2 diabetes mellitus, a worldwide health issue, is a
cluster of metabolic diseases characterized by hypergly-
cemia that result from defects in insulin secretion or/
and action [1]. Numerous lines of evidence support the
involvement of fatty acids in type 2 diabetes mellitus,
and many studies have demonstrated that fatty acids
with different degrees of saturation have different effects
on insulin sensitivity and glucose/lipid metabolism.
Saturated fatty acids are key contributors to insulin
resistance, whereas unsaturated fatty acids have benefi-
cial effects and improve diabetes pathologies through
multiple mechanisms [2,3]. Palmitoleic acid (C16:1) is
an omega-7 monounsaturated fatty acid that is abundant
in plant and marine sources [4-6]. It has been demon-
strated that palmitoleic acid prevents beta-cell apoptosis
induced by glucose or saturated fatty acids [7,8], and
diets rich in palmitoleic acid improve circulating lipid
profile in both animal model [9] and human subjects
[10,11]. Furthermore, a recent report demonstrated that
palmitoleic acid functions as an adipose tissue-derived
lipid hormone that stimulates muscle insulin action and
suppresses hepatosteatosis in mice deficient in fatty acid
binding protein [12]. Very little data are available, how-
ever, concerning the effects of palmitoleic acid on ani-
mal models of diabetes.
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KK-Ay mice are widely used as a model for type 2 dia-
betes [13]. Compared with KK mice, the strain with the
Ay allele (KK-Ay) are obese and develop severe, early-
onset hyperinsulinemia, hyperglycemia, hypertriglyceri-
demia, and fatty liver. In the present study, we examined
the effect of palmitoleic acid on diabetic risk factors in
KK-Ay mice, and further investigated the molecular
mechanisms underlying these effects.
Methods
Materials
Palmitic acid (C16:0) and palmitoleic acid (C16:1 n-7) in
the form of free fatty acids were purchased from Sigma
Chemical Company (St. Louis, U.S.A.) and stored at -20°
C until use. Polyglycerol ester was obtained from Mitsu-
bishi-Kagaku Foods Corporation (Tokyo, Japan). The
fatty acids were dispersed in 1.5% (w/w) of polyglycerol
ester aqueous solution (vehicle) by sonification to a final
concentration of 30 mg/mL. In the preliminary test, the
mean particle diameter and size distribution of fatty
acid solutions were measured using a laser diffraction
particle size analyser (LS 13320, Beckman Coulter Ltd,
Miami FL, USA). All measurements were repeated
twice, and no marked differences in emulsion particle
sizes between palmitic acid and palmitoleic acid solution
were detected (data not shown).
Animals
Six-week-old male KK-Ay mice (SLC, Shizuoka, Japan)
were housed individually in stainless wire mesh cages in
a room with a 12-h light/dark cycle and a constant tem-
perature of 24 ± 1°C. Mice had free access to distilled
water and laboratory chow (Labo MR Stock, Nosan Cor-
poration, Japan) for 1 week to stabilize metabolic condi-
tions. After the stabilization period, 30 mice were
randomly divided into 3 equal groups and orally admi-
nistered either 1.5% (w/w) of polyglycerol ester (vehicle),
300 mg/kg of palmitic acid solution (palmitic acid
group), or 300 mg/kg of palmitoleic acid solution (pal-
mitoleic acid group). These dietary supplements were
provided through a stomach tube each morning between
10:00 and 11:00 for 4 weeks. All mice were allowed free
access to water and chow during the experimental per-
iod. We measured each mouse’s food intake (every 3-4
days) and body weight (once per week) throughout the
experiment. This study was conducted in compliance
with the National Institutes of Health: Guide for the
Care and Use of Laboratory Animals, and the Institu-
tional Animal Care and Use Committee of Japan SLC
Inc. approved the protocol.
Insulin tolerance test
To evaluate effect of palmitoleic acid on insulin sensitiv-
ity, an insulin tolerance test was performed on day 22.
Following 5 h of food deprivation, an insulin solution
(0.5 U/kg body weigh, Humulin R U-100, Eli Lilly,
Japan) was administered subcutaneously. Blood samples
were collected immediately preceding insulin adminis-
tration (0 min), and 30, 60, and 120 min later. Blood
samples were centrifuged at 2,000 × g for 15 min, and
plasma glucose concentrations were measured using a
glucose test kit (Glucose CII-test, Wako Pure Chemical
Industries, Ltd., Japan).
Blood analysis
To determine plasma glucose levels, blood samples
were taken from the retro-orbital venous plexus of
each mouse once per week. Samples were drawn from
animals in a non-fasted state, immediately preceding
administration of the testing materials. On the final
day of the experiment, animals were deprived over-
night food. The next morning, mice were anesthetized
using diethyl ether, and sacrificed by bleeding from the
postcaval vein. The blood was collected, and levels of
plasma triglyceride, total cholesterol, and free fatty
acids were measured using enzyme assay kits (Trigly-
cerol E-Test, Cholesterol E-Test, and NEFA C-Test
reagents, respectively; Wako). Plasma insulin concen-
trations were determined using reagents from an insu-
lin ELISA kit (Morinaga Institute of Biological Science,
Inc., Japan).
Organ measurements
On the final day of the study, vital organs were dissected
and weighed after a short wash in cold phosphate-buf-
fered saline (PBS, pH 7.4). Mesenteric adipose tissue
and livers were maintained at -80°C until analyzed.
Liver triglyceride contents analysis
Liver total lipids were extracted from a portion of the
tissue sample as described by Folch et al. [14]. Extracted
lipids were dried using a vacuum concentrator (Concen-
trator Plus 5305, Eppendorf) and dissolved in 2-propa-
nol containing 10% (w/w) Triton X-100. Triglyceride
concentrations were determined using Wako Triglycer-
ide E-Test.
Oil red O staining of liver sections
Liver samples were washed in cold PBS and fixed over-
night at 4°C with a 4% paraformaldehyde solution in
PBS. Samples were embedded in optimal cutting tem-
perature compound (Tissue-Tek, Sakura Finetek Japan
Co., Ltd.) and frozen at -80°C. Six-μm thick sections
were cut using a cryotome (Jung Frigocut model 2800N,
Leica) at -25°C. Sections were stained for 20 min with
fresh oil red O solution (Sigma). Stained liver sections
were washed thoroughly with distilled water prior to
microscopic observation. Images were captured using an
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Olympus camera mounted on an Olympus upright
microscope.
Real-time polymerase chain reaction (RT-PCR)
Mesenteric adipose tissue and liver total RNA were
extracted with TRIzol reagent (Qiagen, Valencia, CA),
and cDNAs were synthesized from total RNA (1 μg) by
using a PrimeScript 1st-strand cDNA synthesis kit
(TaKaRa Bio, Otsu, Japan) following manufacturer’s pro-
tocols. To quantify mRNA expression levels, the PCR
amplifications of different cDNAs were performed with
SYBR premix Ex Taq (TaKaRa Bio) on the Applied Bio-
systems 7300 Real-Time PCR System (Life Technologies
Co., Japan) according to the manufacturer’s instructions.
The expression levels of target gene were normalized by
the expression of the endogenous control gene encoding
18S ribosomal RNA. The primer sequences used were
shown in Table 1.
Statistical Analysis
Data are expressed as mean ± standard errors (SE). Sta-
tistical analyses with Tukey multiple comparisons test
were performed to determine differences between
groups. The results were considered to be significant if
the value of p was < 0.05.
Results
Effect of palmitoleic acid on body and organ weights
As shown in Table 2, administration of palmitoleic acid
to KK-Ay mice caused a significant decrease (p < 0.05)
in body and liver weights, as well as a marked increase
(p < 0.05) in pancreas weight as compared with the pal-
mitic acid or control group. Mesenteric white adipose
tissue, brown adipose tissue, and skeletal muscle, how-
ever, did not differ significantly among the three groups.
In addition, food intake of the palmitoleic acid group
was lower than in the control group (p < 0.05), whereas
palmitic acid did not affect food intake.
Effect of palmitoleic acid on plasma glucose level
Palmitoleic acid administration significantly decreased (p
< 0.05) plasma glucose levels compared to animals
administered the vehicle alone (Figure 1). In contrast,
Table 1 GenBank accession numbers and primer
sequences used in PT-PCR







TNFa 5’- CCCTCACACTCAGATCATCTTCT-3’ NM_013693
5’-GCTACGACGTGGGCTACAG-3’
Resistin 5’- AAGAACCTTTCATTTCCCCTCCT-3’ NM_022984
5’-GTCCAGCAATTTAAGCCAATGTT-3’
Adiponectin 5’-TGTTCCTCTTAATCCTGCCCA -3’ NM_009605
5’-CCAACCTGCACAAGTTCCCTT-3’
SREBP-1: Sterol regulatory element binding protein 1, FAS: Fatty acid synthase,
SCD-1: Stearoyl CoA desaturase-1, TNFa: Tumor necrosis factor alpha.
Table 2 Body weights, food intakes, organ weights and
plasma lipid levels
Control C16:0 C16:1
Initial body weight (g) 30.0 ± 0.3 30.1 ± 0.3 30.8 ± 0.4
Final body weight (g) 36.7 ± 0.5a 35.3 ± 0.7a 32.1 ± 1.1b
Food intake (g/day) 6.1 ± 0.1a 5.8 ± 0.2a 5.1 ± 0.3b
Organ weights
Liver (mg/g BW) 46.9 ± 1.3a 46.3 ± 1.3a 40.2 ± 0.9b
Pancreas (mg/g BW) 9.6 ± 0.2a 10.2 ± 0.2a 11.2 ± 0.3b
Mesenteric WAT (mg/g
BW)
21.2 ± 0.9 21.1 ± 0.4 19.1 ± 1.2
BAT (mg/g BW) 7.2 ± 0.5 7.1 ± 0.4 7.6 ± 0.4
Skeletal muscle (mg/g
BW)
8.8 ± 0.3 8.6 ± 0.3 9.1 ± 0.5
Plasma lipid parameters






Total cholesterol (mg/dL) 112.7 ± 8.2 99.4 ± 5.9 109.7 ± 4.6
Free fatty acid (mEq/L) 0.49 ± 0.03 0.48 ± 0.02 0.48 ± 0.03
KK-Ay mice were orally administrated vehicle (control), 300 mg/kg of palmitic
acid, or 300 mg/kg palmitoleic acid on a daily basis for 4 weeks. Values are
means ± SE, n = 10. Means in a row with superscripts without common letter
are different, p < 0.05. C16:0, palmitic acid; C16:1, palmitoleic acid; BW, body


























Figure 1 Effect of palmitoleic acid on plasma glucose
concentrations in KK-Ay mice. Animals were orally administered
vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg
palmitoleic acid on a daily basis for 4 weeks. Values are means ± SE,
n = 10. *p < 0.05 compared with the control group. C16:0, palmitic
acid; C16:1, palmitoleic acid.
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plasma glucose concentrations did not differ between
the palmitic acid and control groups.
Effect of palmitoleic acid on insulin sensitivity
When animals were subjected to an insulin tolerance
test, plasma glucose levels decreased more rapidly in the
palmitoleic acid group than in the control group (Figure
2A). In the palmitoleic acid group, plasma glucose con-
centrations were lower than in the control group at 60
min (p < 0.05) following a single subcutaneous adminis-
tration of insulin. Plasma glucose levels did not differ
between the palmitic acid group and control group.
Insulin resistance precedes diabetes onset in KK-Ay
mice and typically causes higher plasma insulin levels.
As shown in Figure 2B, plasma insulin levels were mark-
edly lower (p < 0.05) in palmitoleic acid than in the pal-
mitic acid or control group.
Effect of palmitoleic acid on plasma lipids
Palmitoleic acid treatment significantly decreased plasma
levels of triglyceride (p < 0.05) (Table 2), when com-
pared to the palmitic acid or control group. No changes
were detected, however, in plasma levels of total choles-
terol or free fatty acid.
Effect of palmitoleic acid on liver lipids
Administration of palmitoleic acid led to a noticeable
decrease (p < 0.05) in hepatic triglyceride levels (Figure
3A) compared to either the palmitic acid or control
group. Oil red O staining of liver sections revealed neu-
tral lipid content. This analysis indicated that palmito-
leic acid reduced hepatic neutral lipid accumulation in
KK-Ay mice (Figure 3B III) compared to the control
group (Figure 3B I). In contrast, no differences were
observed between the control and palmitic acid groups
(Figure 3B II).
Effect of palmitoleic acid on mRNA Levels of lipogenic
genes in liver
As shown in Figure 4, SREBP-1 (p < 0.05), FAS (p <
0.05), and SCD-1 (p < 0.05) mRNA levels in the palmi-
toleic acid group were significantly lower than the
respective levels in the palmitic acid group or control
group. However, there were no changes in these lipo-
genic gene mRNA expressions between the palmitic acid
and control group.
Effect of palmitoleic acid on adipocytokine mRNA Levels
in adipose tissue
We measured mRNA levels of adipocytokines that are
reported to influence insulin sensitivity (Figure 5). As
compared to the palmitic acid or control group, mRNA
levels of TNFa and resistin in mesenteric adipose tissue
were markedly suppressed (p < 0.05) by the
administration of palmitoleic acid for 4 weeks, though
no changes in these data were found between the palmi-
tic acid and control group. On the other hand, adipo-
nectin mRNA expression levels did not differ between
the control and palmitic acid and palmitoleic acid
groups.
Discussion
Our results demonstrate that palmitoleic acid positively
affects hyperglycemia, hypertriglyceridemia, and insulin
resistance in spontaneously diabetic KK-Ay mice. Risk
factors for type 2 diabetes mellitus include insulin resis-
tance, hyperglycemia, dyslipidemia, and metabolic syn-





















0 30 60 120 




























Figure 2 Effect of palmitoleic acid on insulin resistance in KK-Ay
mice. Animals were orally administered vehicle (control), 300 mg/kg of
palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis for 4
weeks. (A) Plasma glucose levels in an insulin tolerance test. The insulin
tolerance test was carried out on day 22 of the 4-week experiment.
Animals were deprived of food for 5 h before administration of the
insulin. Blood samples were collected immediately before the insulin
injection (0 min) and 30, 60, and 120 min later. Values are means ± SE,
n = 10. p < 0.1 and *p < 0.05 compared with the control group. (B)
Plasma insulin levels. Blood samples were collected at the end of 4-
week experiment after over-night fasting. Means in a row with
superscripts without common letter are different, p < 0.05. C16:0,
palmitic acid; C16:1, palmitoleic acid.
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metabolic perturbation. Insulin resistance is character-
ized by reduced responsiveness of target tissues (liver,
skeletal muscle, adipocytes) to normal circulating levels
of insulin, followed by a progressive decline in insulin
secretion from the pancreas [15]. Free fatty acids (satu-
rated fatty acids, in particular) promote insulin resis-
tance and reduce glucose utilization in skeletal muscle
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Figure 3 Effect of palmitoleic acid on hepatic steatosis in KK-
Ay mice. Animals were orally administered vehicle (control), 300
mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily
basis for 4 weeks. Graphs depicting neutral lipid accumulation in
liver tissue are shown. (A) Hepatic triglyceride concentration. Values
are means ± SE, n = 10. Means in a row with superscripts without
common letter are different, p < 0.05. C16:0, palmitic acid; C16:1,
palmitoleic acid. (B) Oil red O staining of liver sections from control
(I), palmitic acid (II), and palmitoleic acid (III) groups of KK-Aymice.
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Figure 4 Effect of palmitoleic acid on lipogenic gene
expression in liver in KK-Ay mice. Animals were orally
administered vehicle (control), 300 mg/kg of palmitic acid, or 300
mg/kg palmitoleic acid on a daily basis. (A) Relative mRNA
expression levels of SREBP-1; (B) Relative mRNA expression levels
of FAS; (C) Relative mRNA expression levels of SCD-1. Each value is
the mean ± SE, n = 10. Means in a row with superscripts without
common letter are different, p < 0.05. C16:0, palmitic acid; C16:1,
palmitoleic acid; SREBP-1, sterol regulatory element binding
protein 1; SCD-1, stearoyl-coenzyme A desaturase 1; FAS, fatty acid
synthase.
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monounsaturated palmitoleic acid improves glycemic
control and increases glucose transport into skeletal
muscle cells. This effect is mediated, at least in part, by
upregulation of the activities of the glucose transporters
GLUT1 and GLUT4 [18,19]. Hyperinsulinemic-euglyce-
mic clamp studies have shown that palmitoleic acid, in
the form of a triglyceride, potentiates the insulin-signal-
ing pathway in mice [12]. In the present study, adminis-
tration of palmitoleic acid, but not palmitic acid,
improved insulin resistance. It is likely, therefore, that
the effects of palmitoleic acid on hyperglycemia and
hypertriglyceridemia can be attributed to improved insu-
lin sensitivity.
To investigate the possible mechanisms behind the
beneficial effect of palmitoleic acid on insulin sensitivity,
we extended our study to examine adipocytokine gene
expression. Numerous studies have shown the close
relationship between insulin resistance-linked type 2 dia-
betes and adipocytokines that are mainly derived from
adipose tissue [20,21]. Adiponectin, a key adipocytokine,
has been shown to increase insulin sensitivity at least in
part through stimulating b-oxidation in skeleton muscle
and decreasing hepatic glucose output [22]. However,
adiponectin mRNA expression levels did not change by
palmitoleic acid administration in the present study,
suggesting a minor effect of palmitoleic acid on adipo-
nectin on a gene expression level. On the other hand,
repeated administration of palmitoleic acid down-regu-
lated mRNA expressions of TNFa and resistin, the adi-
pocytokines that have been demonstrated to contribute
to insulin resistance [23,24]. It is thereby suggested that
the beneficial effect of palmitoleic acid on improvement
of insulin resistance may be partially owed to suppres-
sing proinflammatory gene expression. In addition, our
results also show that pancreas weight increased by
repeated administration of palmitoleic acid. In type 2
diabetes, the pancreas fails to produce enough insulin,
and evidence suggests that loss of beta cells contributes
to this impairment [25,26]. Preventing beta-cell apopto-
sis and promoting its proliferation, therefore, may repre-
sent an important mechanism for improving the
diabetic condition. In vitro studies have shown that pal-
mitoleic acid prevented the beta cells from high glucose-
and palmitic acid-induced impairment of beta-cell pro-
liferation possibly via induction of Bcl-2 [27]. Neverthe-
less, how palmitoleic acid improves beta-cell function
and in turn ameliorates insulin resistance in diabetic
model has not been entirely elucidated.
Our present data show that palmitoleic acid sup-
presses lipid accumulation in the liver. To investigate its
mechanism, we assessed liver mRNA levels of genes
involved in lipogenesis. Analysis of gene expression with
RT-PCR indicated that palmitoleic acid markedly down-



































































































Figure 5 Effect of palmitoleic acid on adipocytokine mRNA
levels in adipose tissue in KK-Ay mice. Animals were orally
administered vehicle (control), 300 mg/kg of palmitic acid, or 300
mg/kg palmitoleic acid on a daily basis. (A) Relative mRNA
expression levels of TNFa; (B) Relative mRNA expression levels of
resistin; (C) Relative mRNA expression levels of adiponectin. Each
value is the mean ± SE, n = 10. Means in a row with superscripts
without common letter are different, p < 0.05. C16:0, palmitic acid;
C16:1, palmitoleic acid; TNFa, Tumor necrosis factor alpha.
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SREBP-1, FAS and SCD-1. SREBP-1 and its target genes
FAS as well as SCD-1 are involved in adipogenesis, and
SREBP-1 play a central role in regulating fatty acid
metabolism [28]. Suppressing effect of palmitoleic acid
on hepatic lipid accumulation is thereby possibly due to
inhibiting de novo lipogenesis. Cao et al. [12] demon-
strated that fatty acid binding protein-deficient mice
have dramatically elevated levels of circulating palmito-
leic acid compared to wild-type mice, and that high
levels of palmitoleic acid down-regulate genes involved
in de novo lipogenesis within the liver. It has been
reported that hepatic lipid accumulation closely corre-
lates with obesity, insulin resistance, and type 2 diabetes
mellitus [29]. In the liver, insulin suppresses hepatic glu-
cose output by inhibiting gluconeogenesis and stimulat-
ing glycogen synthesis [30]. In contrast, hepatic steatosis
seems to stimulate gluconeogenesis by activating protein
kinase C epsilon type and c-Jun N-terminal kinase 1
[31]. These activated proteins subsequently interfere
with tyrosine phosphorylation of insulin receptor sub-
stance 1 and 2 and impair the ability of insulin to acti-
vate glycogen synthase. We therefore infer that
palmitoleic acid improves insulin resistance in diabetic
mice, at least in part by decreasing hepatic lipid
accumulation.
A growing body of evidence indicates that excess body
weight is linked to type 2 diabetes [32,33]. Administra-
tion of palmitoleic acid to KK-Ay mice reduced body
weight gain, which may in turn have improved glucose
and lipid metabolism. Interestingly, palmitoleic acid
treatment resulted in a lower food intake compared
with the control group, and studies have shown favor-
able effects of low calorie intake on obesity-induced
metabolic disorders possibly by improving insulin sensi-
tivity [34,35]. Some unsaturated fatty acids, such as the
n-3 polyunsaturated eicosapentaenoic acid and docosa-
hexaenoic acid, as well as some short-chain saturated
fatty acids, have been shown to regulate secretion of
hunger hormones (e.g., the adipose tissue-derived hor-
mone leptin) and gastrointestinal peptides (e.g., gluca-
gon-like peptide-1, cholecystokinin) [36-39]. On the
other hand, levels of hunger hormones correlate with
energy intake and glucose metabolism [40-42]. The
mechanisms by which palmitoleic acid affects food
intake, however, remain unresolved.
Conclusions
In conclusion, oral administration of palmitoleic acid to
KK-Ay mice dramatically improved their diabetic condi-
tion. Body weight increases, hyperglycemia, and hyper-
triglyceridemia were all reduced in response to
palmitoleic acid. In these mice, down-regulation of
proinflammatory gene expressions and decreased hepatic
lipid accumulation improved insulin sensitivity, which
likely led to many of the beneficial effects documented
in this study.
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